Channel Therapeutics Corporation
Channel Therapeutics Corporation (CHRO) Revenue
Annual & quarterly revenue history · segment & region breakdown
CHRO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsChannel Therapeutics Corporation trailing twelve-month (TTM) revenue is $0.03B, an increase of 0.00% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2020 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.02B | +$0.02B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Channel Therapeutics Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Channel Therapeutics Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Channel Therapeutics Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CHRO revenue · 4 questionsCHRO's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 0.00% year-over-year from $0.02B in FY2025.
▸ Source: FMP · Channel Therapeutics Corporation SEC filings · GAAP · Channel Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026